Verizon to cut 15,000 jobs amid growing competition pressures - WSJ
Investing.com -- Coloplast delivered a solid fourth-quarter performance, with in-line organic sales growth (OSG) matching expectations and margins beating forecasts.
Shares in the medical equipment maker rose 1.7% in Copenhagen after the report.
Organic sales rose 7% year on year, in line with consensus and accelerating from 6.7% in the previous nine months. The strongest growth came from Voice and Respiratory Care and Continence Care, both up 9%, while Ostomy Care gained 7%.
Advanced Wound Care rose 5%, held back by continued recall-related headwinds, though Kerecis showed strong recovery with a 20% increase in the quarter.
Operating profit before special items came in at DKK 1.95 billion, 3% above consensus, translating to a margin of 28.0% versus 26.8% expected.
"Q4 mgin of 28.0% is markedly above consensus of 26.8%, despite an 80bp FX headwind," Jefferies analyst Julien Dormois said.
Gross margin improved to around 68%, supported by easing input costs, price increases, and favorable product mix, partly offset by ramp-up expenses for new facilities in Costa Rica and Portugal.
For fiscal 2025/26, Coloplast guided for organic sales growth of about 7% and EBIT growth in constant currency roughly in line with or slightly above sales. Dormois said the guidance reflects “a slow start to the Impact4 strategy."
Still, he added that "COLOB remains a key pick thanks to sector-leading growth profile, reset expectations, no tariff exposure and appealing valuation. All eyes remain on a new CEO being appointed."